Directors’ Choice Series Launches at tri
Session 1
Would you like to know what an editor looks for when picking journals? This session will provide you with insights from current and past editors and includes common pitfalls made when preparing papers. This four part series will cover various topics related to publishing in 2020. The first session, titled ‘Which journal and why’ kicks off on Tuesday 26 May at 12pm.
The first speaker is TRI CEO, Prof Scott Bell who is also the current editor of the Journal of Cystic Fibrosis. Prof Bell will explain and discuss what an Editor wants to know when you submit your paper.
Joining Prof Bell will be editor Prof Nikolas Haass, Head of the Experimental Melanoma Therapy Group at UQDI, giving an editor’s perspective on selecting the right destination.
Following Prof Haass will be UQDI’s A/Prof Fiona Simpson, Principal Fellow of the Queensland Head and Neck Cancer Centre, who will be providing an author’s perspective.
At the end of these presentations there will be opportunities for questions to our panel chaired by Mater Research Officer, Dr Anuj Sehgal.
Please note this is a Zoom seminar only. To join us via Zoom Video Conference, use Meeting ID: 841 9204 8831
Date: Tuesday 26 May
Time: 12pm-1pm
This seminar will also be recorded, if you would like access to the recording please email [email protected]
| Speaker | Bio |
|
|
Professor Bell has more than 230 peer-reviewed publications and has received grant support in excess of $20 million over the past 10 years. His research interests include Cystic Fibrosis Microbiology and acquisition pathways from human infection. He is the Editor-in-Chief of the Journal of Cystic Fibrosis, and in the last two years, he has published research in 18 different journals including: American Journal of Respiratory and Critical Care Medicine, Thorax, Respirology, Cochrane Database of Systematic Reviews and Frontiers in Immunology. |
|
|
Professor Haas obtained his PhD at the University of Heidelberg after which he trained as a dermatologist with a focus on skin cancers. He undertook post-doctoral fellow roles at the Wistar Institute/University of Pennsylvania and the Centenary Institute, Sydney. At UQDI his focus is studying the diversity and behaviour of melanoma tumour cells as well as their interaction with the microenvironment surrounding them. Professor Haas has held editorial board member positions with PLoS ONE, Arch Dermatol Res, Exp Dermatol and Pharmacol Res. Recent publications of his work were included in journals such as the International Journal of Cancer, Biophysical Journal, and Frontiers in Medicine. |
|
|
A/Prof Simpson completed her PhD at Cambridge University before completing post-doctoral fellow roles at the Scripps Institute and The University of Queensland. Her research group at UQDI has a focus on translating research findings into new cancer therapies. Under her leadership, the group has generated a novel method for antibody-mediated cancer therapy along with associated companion diagnostic methods. A/Prof Simpson was the Lead scientific investigator on a Phase I proof of concept study of the novel therapy in head and neck cancer and is the Lead scientific Investigator on forthcoming Phase II clinical trials in advanced cancer. Her research has been published in journals including: Cell, International Journal of Cancer, Journal of Investigative Dermatology, OncoImmunology and PLoS One. |
